Mologen–Signal Iduna: investment, 201512 existing investor Deutscher Ring Krankenversicherung holding estimated 6% in Mologen |
2015-12-31 |
Boehringer–Polyphor: drug discovery, 201512 collab existent to identify + optimise drug candidates using macrocycle platform |
2015-12-22 |
Convergence Pharmaceuticals–Evotec: investment, 201512 acquisition of 51% of shares of Panion Ltd |
2015-12-09 |
Bridgepoint–Kohlberg Kravis Roberts: investment, 201512 acquisition €na of LGC by KKR from Bridgepoint |
2015-12-08 |
TiGenix–Cormorant Asset Management: investment, 201511 private placement totalling €8.7m incl €4.7m to Cormorant Global Healthcare |
2015-11-25 |
TiGenix–SEVERAL: investment, 201511 private placement €8.7m with 9.1m new shares €0.95/share to Cormorant + European institutional investors |
2015-11-25 |
Omeicos–Germany (govt): grant, 201511– BMBF research grant €1.7m |
2015-11-02 |
MTIP MedTech Innovation Partners–SEVERAL: investment, 201511–201604 1st closing CHF30m of 1st MTIP Fund |
2015-11-01 |
Tusk Therapeutics–SEVERAL: investment, 201511 financing round Series A €30m |
2015-11-01 |
Arvinas–SEVERAL: investment, 201510 financing round Series B $41.6m led by RA Capital Management |
2015-10-21 |
Science 37–Novartis: investment, 201510 financing round Series A totalling $6.5m co-led by Lux Capital + dRx Capital |
2015-10-20 |
Science 37–SEVERAL: investment, 201510 financing round Series A $6.5m co-led by Lux Capital + dRx Capital |
2015-10-20 |
Zavante Therapeutics–SEVERAL: investment, 201510 seed financing round |
2015-10-09 |
Roche–Arvinas: protein degradation drugs, 201510– strategic license multi-year for PROTAC technology to Genentech |
2015-10-01 |
Taisho–Polyphor: drug discovery, 201509– collab €na identification of drug candidates using macrocycle platform |
2015-09-17 |
Baxalta–Novimmune: therapeutic antibodies, 201509– collab RnD €na bispecific antibodies for hemophilia A |
2015-09-02 |
Intellia Therapeutics–Novartis: investment, 201509 financing round Series B totalling $70m led by OrbiMed + incl co-investor Novartis |
2015-09-01 |
Intellia Therapeutics–SEVERAL: investment, 201509 financing round Series B $70m led by OrbiMed HealthCare Fund Management |
2015-09-01 |
Protembis–SEVERAL: investment, 201507 seed financing round 7-digit € incl Innovationsstarter Fonds + Geratherm + angel investors |
2015-07-28 |
Accurate Mass Scientific–CovalX: mass spectrometry, 201507– collab AMS new Australian distributor of CovalX High-Mass systems + CRO analytics services |
2015-07-15 |
AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock |
2015-07-14 |
ViraTherapeutics–Austria (govt): investment, 201506 financing round Series A 1st closing totalling €3.6m incl co-investor aws |
2015-06-23 |
ViraTherapeutics–Boehringer: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures |
2015-06-23 |
ViraTherapeutics–EMBL: investment, 201506 financing round Series A 1st closing totalling €3.6m co-led by BIVF + EMBL Ventures |
2015-06-23 |
Juno Therapeutics–Editas Medicine: cancer immunotherapy, 201505– strategic alliance to develop CAR-T + engineered TCR therapies |
2015-05-27 |
Arcus Biosciences–Novartis: investment, 201505 financing round Series A totalling $49.7m incl co-investor Novartis |
2015-05-01 |
Arcus Biosciences–SEVERAL: investment, 201505 financing round Series A $49.7m incl F&F + Column Group + Foresite Capital + Novartis + Celgene |
2015-05-01 |
Cyclenium–Haplogen: virostatic agents, 201505– collab drug discovery small molecule macroycle inhibitors using CMRT technology |
2015-05-01 |
Blueberry Therapeutics–SEVERAL: investment, 201504 financing round $1.75m from UK + Swiss investors |
2015-04-08 |
Caribou Biosciences–SEVERAL: investment, 201504 financing round Series A $11m incl Fidelity Biosciences + Novartis + Mission Bay Capital et al |
2015-04-02 |
Macrolide–Bertarelli Group: investment, 201503 financing round Series A totalling $22m inc co-lead investor Gurnet Point Capital |
2015-03-04 |
Macrolide–GSK: investment, 201503 financing round Series A totalling $22m inc co-lead investor SROne |
2015-03-04 |
Macrolide–Novartis: investment, 201503 financing round Series A totalling $22m inc co-lead investor Novartis Venture Fund |
2015-03-04 |
Macrolide–Roche: investment, 201503 financing round Series A totalling $22m inc co-lead investor Roche Ventures |
2015-03-04 |
Macrolide–SEVERAL: investment, 201503 financing round Series A $22m led by NVF + Gurnet Point + Roche Ventures + SR One |
2015-03-04 |
OpGen–SEVERAL: investment, 201503–201505 IPO $17.1m+$2.565m with 2.85m+427.5k units consisting of 1 share + 1 warrant at $6/unit |
2015-03-03 |
Genenta Science–SEVERAL: investment, 201503 financing round Series A €10m |
2015-03-01 |
Canbex Therapeutics–Ipsen: investment, 201502 Ipsen pays €6m upfront for option to acquire Canbex upon Ph2a completion of VSN16R in MS spasticity |
2015-02-24 |
R2R Biofluidics project–EU (govt): grant, 201502–201901 H2020 grant €6.4m out of total budget of €7.9m |
2015-02-01 |
ASPEC Technologies–CovalX: mass spectrometry, 201501 collab existent ASPEC is distributor of CovalX High-Mass systems in China |
2015-01-15 |
Boehringer–Vanderbilt Univ: Ras inhibitors, 201703– collab expansion RnD small-molecule KRAS inhibitors for cancer |
2015-01-13 |
Aquila Biolabs–SEVERAL: investment, 2015 seed financing round 7-digit € |
2015-01-01 |
Atomwise–SEVERAL: investment, 2015 seed financing round incl Y Combinator + Khosla Ventures + DJF |
2015-01-01 |
Biocentric–Hain Lifescience: investment, 2015 acquisition of Biocentric by Hain |
2015-01-01 |
GreenBone–SEVERAL: investment, 2015 seed financing round €3m from ZernikeMeta Ventures + Italian Angels for Growth + private investors |
2015-01-01 |
IFM Therapeutics–Atlas Venture: investment, 2015 seed funding by Atlas Venture |
2015-01-01 |
Jecure Therapeutics–Versant Ventures: investment, 2015 seed financing from founding investor Versant Ventures |
2015-01-01 |
KBI BioPharma–JSR Corp: investment, 2015 acquisition of KBI BioPharma Inc by JSR Corp |
2015-01-01 |
Kurma–SEVERAL: investment, 2015 final closing €35m of Kurma Diagnostics Fund (KDx) |
2015-01-01 |
Novartis–Fraunhofer: cell therapy production, 201501– collab developm of production capacity for Kymriah in Europe at Fraunhofer IZI |
2015-01-01 |
Novartis–Fraunhofer: cell therapy production, 201808– service supply production of Kymriah in Europe by Fraunhofer IZI |
2015-01-01 |
Numares–SHS: investment, 2015 existent SHS Gesellschaft für Beteiligungsmanagement is main shareholder |
2015-01-01 |
Roche–4D Molecular Therapeutics: gene delivery technology, 2015– collab research |
2015-01-01 |
VIB–Lipotype: mass spectrometry services, 2015– collab supply of shotgun lipidomics services by Lipotype to researchers at VIB |
2015-01-01 |
ViraTherapeutics–Austria (govt): investment, 2015c financing €1.6m from FFG + aws seed financing programme |
2015-01-01 |
Pieris–Ally Bridge Group: investment, 201412 private placement totalling $13.56m incl investor ABG |
2014-12-18 |
Annexon–Clarus Ventures: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Clarus Ventures |
2014-12-15 |
Annexon–Novartis: investment, 201412 financing round Series A-1 totaliing $34m incl lead investor NVF |
2014-12-15 |
Annexon–Satter Investment Management: investment, 201412 financing round Series A-1 totaliing $34m incl co-investor Satter |
2014-12-15 |
Annexon–SEVERAL: investment, 201412 financing round Series A-1 $34m led by NVF + incl Satter Investment + Clarus Ventures |
2014-12-15 |
Tiziana–Novimmune: therapeutic antibody, 201412– license to foralumab (NI-0401) to Tiziana |
2014-12-01 |
Pepperprint–Sciomics: microarray technology, 201411– collab distribution + marketing for antibody characterisation + biomarker discovery |
2014-11-18 |
Roche–NewLink Genetics: cancer drugs, 201410– collab drug discovery IDO/TDO inhibitors with Genentech |
2014-10-16 |
Ipsen–MHH: rec botulinum neurotoxin, 201409– collab RnD with Thomas Binz at Institute for Physiological Chemistry at MHH |
2014-09-01 |
i3 Membrane–SEVERAL: investment, 201408 investment by HTGF + Innovationsstarter Fonds Hamburg |
2014-08-01 |
Geisinger–Indivumed: tissue bank, 201407– collab to create cancer research biobanks at Geisinger + Indivumed |
2014-07-15 |
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie |
2014-07-01 |
B Braun–CeGaT: personalised medicine, 201406 collab establishment of B Braun CeGaT LLC in Pennsylvania |
2014-06-01 |
Novartis–Ophthotech: pegpleranib, 201405– excl license + commercialisation agreem outside of US |
2014-05-01 |
Essen BioScience–SFW Capital Partners: investment, 201405 strategic investment in Essen BioScience by SFW |
2014-04-15 |
Roche–Oryzon Genomics: LSD1 inhibitors, 201605–201707 collab extension developm of ORY-1001 TERMINATED 7/17 |
2014-04-07 |
Synaffix–Aravis: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
Synaffix–BioGeneration Ventures: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
Synaffix–BOM Capital: investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
Synaffix–Merck (DE): investment, 201402 financing round Series A incl Aravis + BioGeneration Ventures + MS Ventures + BOM Capital |
2014-02-18 |
CeeTox–Cyprotex: investment, 201401 acquisition of assets + business of CeeTox by Cyprotex |
2014-01-01 |
Electrochaea–SEVERAL: investment, 2014 financing round Series A |
2014-01-01 |
Horizon Discovery–ERS Genomics: CRISPR technology, 2014– license ww non-excl to Horizon |
2014-01-01 |
Mestex–SEVERAL: investment, 2014 1st financing round |
2014-01-01 |
Provecs–Cevec: rec protein production technology, 2014– license to CAP GT technology for cancer immunotherapy |
2014-01-01 |
Rebiotix–SEVERAL: investment, 2014 financing round Series B $25m |
2014-01-01 |
Sirion Biotech–LaVoieHealthScience: public relations, 2014– supply service US PR/IR |
2014-01-01 |
Tusk Therapeutics–Droia Ventures: investment, 201809 existent majority shareholder + founding investor Droia Oncology Ventures |
2014-01-01 |
Sirion Biotech–Cevec: cell lines, 201312– license €na to CAP cell lines for expression of AAV vectors |
2013-12-19 |
Eloxx Pharmaceuticals–SEVERAL: investment, 201311 initial closing of 1st financing round with Roche + Pontifax |
2013-11-21 |
Mission Therapeutics–Roche: investment, 201311 financing round Series B totalling £20m incl existing investor Roche Venture Fund |
2013-11-18 |
Polymedco–Epigenomics: molecular diagnostics, 201310– collab joint commercialisation of Epi proColon test in North America |
2013-10-02 |
Gardner Denver–Kohlberg Kravis Roberts: investment, 201307 acquisition 100% for $3.9b incl assumption of debt |
2013-07-16 |
Bruker–3M: MALDI Imaging, 201609– license expansion excl to technique for performing MS analysis on FFPE tissue for pathology |
2013-06-04 |
Allecra Therapeutics–EMBL: investment, 201304 financing round Series A totalling €15m incl co-investor EMBL Ventures |
2013-04-18 |
Allecra Therapeutics–Forbion: investment, 201304 financing round Series A totalling €15m incl co-lead investor Forbion |
2013-04-18 |
Allecra Therapeutics–LCF Rothschild: investment, 201304 financing round Series A totalling €15m incl co-lead investor EdRIP |
2013-04-18 |
ABF–Genedata: bioinformatics, 2013– supply use of Genedata Selector by AB Enzymes for strain genome data management |
2013-01-01 |
BioNTech–MAB Discovery: antibody technology, 2013– collab mAb generation using technology of MAB Discovery |
2013-01-01 |
Boehringer–Qiagen: molecular companion diagnostics, 2013 collab existent incl therascreen EGRF RGQ PCR Kit for Giotrif |
2013-01-01 |
Kaiser Optical Systems–Endress+Hauser: investment, 2013 acquisition by Endress+Hauser |
2013-01-01 |
PlasmidFactory–Sirion Biotech: gene delivery technology, 201212– collab pronotion of AAV vectors for preclinical ersearch |
2012-12-04 |
Roche–AC Immune: therapeutic antibodies, 201206– license excl for anti-Tau program for Alzheimer’s disease to Genentech |
2012-06-01 |
B Braun–CeGaT: personalised medicine, 201201– collab strategic partnership to expand + internationalise CeGaT’s business |
2012-01-31 |
Bayer–X-Chem: small-molecule drug discovery, 2012– collab research using DEX technology |
2012-01-01 |